Kineta Inc.
Kineta Inc.
Kineta Inc.
Close
  • about
    • company
    • team
    • board
    • SAB
  • pipeline
    • overview
    • KVA12123 (VISTA)
    • CD27
  • partnerships
  • investors
    • overview
    • press releases
    • events & presentations
    • stock information
    • analyst coverage
    • SEC filings
    • corporate governance
    • IRS Form 8937
  • careers
  • contact
  • en_USEnglish
    • ko_KRKorean
  • about
    • company
    • team
    • board
    • SAB
  • pipeline
    • overview
    • KVA12123 (VISTA)
    • CD27
  • partnerships
  • investors
    • overview
    • press releases
    • events & presentations
    • stock information
    • analyst coverage
    • SEC filings
    • corporate governance
    • IRS Form 8937
  • careers
  • contact
  • en_USEnglish
    • ko_KRKorean

[be_recent_posts_author_no_link title=”Latest News from Kineta” category_id=”4,3″ num_posts=”6″ post_offset=”0″ num_words_limit=”0″ show_date_author=”1″ show_more_link=”0″ more_link_text=”Read more” show_thumbs=”0″ remove_thumb_frame=”0″ thumb_frame_shadow=”0″ default_thumb=”0″ post_thumb_width=”100″ post_thumb_height=”80″]

Recent Kineta News

  • Kineta Announces Participation at October Investor Conferences
  • Kineta to Present New Preclinical Data on Lead Anti-CD27 Agonist Antibody at AACR Special Conference on Tumor Immunology and Immunotherapy
  • Kineta Announces New Research Agreement to Evaluate VISTA Biomarker Expression
  • Kineta to Participate in Upcoming Investor Conferences
  • Kineta Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Post placeholder image
June 6, 2022 in Biotech Industry News

GeekWire: Seattle biotech Kineta will go public in deal with neurosciences company Yumanity Therapeutics

Kineta Inc 6 Like Post Comments Off on GeekWire: Seattle biotech Kineta will go public in deal with neurosciences company Yumanity Therapeutics
Read More
Post placeholder image
June 6, 2022 in Kineta Press Release

Kineta Announces Reverse Merger with NASDAQ-listed Yumanity Therapeutics (YMTX)

Kineta Inc 4 Like Post Comments Off on Kineta Announces Reverse Merger with NASDAQ-listed Yumanity Therapeutics (YMTX)

Yumanity Therapeutics announces definitive agreements for two strategic transactions Yumanity Therapeutics, Inc. to sell its clinical-stage product candidate YTX-7739 as well as its unpartnered disco ...

Read More

219 Terry Ave. N. Suite 300. Seattle, WA 98109

Sign Up for Email Alerts

219 Terry Ave. N. Suite 300. Seattle, WA 98109

  • about
  • pipeline
  • partnerships
  • investors
  • contact
Sign Up for Email Alerts

© 2023 Kineta Inc.        Privacy Policy       Terms of Use

English
English
Korean